Discovery of matrix metalloproteases selective and activated peptide–doxorubicin prodrugs as anti-tumor agents

Discovery of matrix metalloproteases selective and activated peptide–doxorubicin prodrugs as anti-tumor agents Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin Development and in vitro efficacy of novel MMP2 and MMP9 specific doxorubicin albumin conjugates Rationalized Computer-Aided Design of Matrix-Metalloprotease-Selective Prodrugs Novel Peptide–Doxorubucin Conjugates for Targeting Breast Cancer Cells Including the Multidrug Resistant Cells The Synthesis of a Prodrug of Doxorubicin Designed to Provide Reduced Systemic Toxicity and Greater Target Efficacy Synthesis and Biological Evaluation of Novel Prodrugs of Anthracyclines for Selective Activation by the Tumor-Associated Protease Plasmin Development of dual-acting prodrugs for circumventing multidrug resistance Development of Novel Bisphosphonate Prodrugs of Doxorubicin for Targeting Bone Metastases That Are Cleaved pH Dependently or by Cathepsin B: Synthesis, Cleavage Properties, and Binding Properties to Hydroxyapatite As Well As Bone Matrix Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate